The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

Inclusion Criteria:

• Biopsy confirmation of Breast Cancer

• Breast Cancer has continued to grow after having received treatment with an aromataseinhibitor

• Postmenopausal women defined as a women who has stopped having menstrual periods

• Evidence of hormone sensitivity

• Written informed consent to participate in the trial

Exclusion Criteria:

• Previous treatment with Faslodex (fulvestrant) or Aromasin (exemestane)

• Any hormonal therapy used to modify the course of an additional medical conditionafter prior treatment with a non-steroidal aromatase inhibitor

• Treatment with an investigational or non-approved drug within one month

• An existing serious disease, illness, or condition that will prevent participation orcompliance with study procedures

• A history of allergies to any active or inactive ingredients of Faslodex or Exemestane (i.e. castor oil or Mannitol)